hotspot -WSS

hotspot

author：fashion 2025-10-01 04:45:06 - browse：3277

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： How the Dana

entertainment

WSS

How the Dana

Apple Watch's A

Brain worms: The science behind RFK Jr.'s parasitic infection

Covid vaccines: Private market messier than government rollout

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Use wet bulb globe temperature, not heat index, to protect workers

knowledge

hotspot

hotspot

Jerome Adams on the need for new antivirals for Covid

Paxlovid should be available without a positive Covid test

Medicare details structure of new drug price negotiation program

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Heart attack and stroke risk calculators need revising

Intercept Pharmaceuticals sells itself for less than $1 billion

Medical records are filled with copy

Medicare says breakthrough device reimbursement rule to come by summer

The high cost of giving birth even with insurance

After a drawn out lobbying fight, ARPA

explore

Making AI in medicine accessible to smaller, and rural hospitals

Medicaid, Medicare dual

Study: AI not yet building 'n

Study: Adult vaccinations pay for themselves in societal benefits

FDA advisers vote against ALS treatment from BrainStorm

Google says AlphaFold 3 can map a vast universe of biomolecules

knowledge

entertainment

entertainment

explore